» Articles » PMID: 31035923

The Effect of Orofacial Complete Freund's Adjuvant Treatment on the Expression of Migraine-related Molecules

Overview
Journal J Headache Pain
Publisher Biomed Central
Date 2019 May 1
PMID 31035923
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Migraine is a neurovascular primary headache disorder, which causes significant socioeconomic problems worldwide. The pathomechanism of disease is enigmatic, but activation of the trigeminovascular system (TS) appears to be essential during the attack. Migraine research of recent years has focused on neuropeptides, such as calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide 1-38 (PACAP1-38) as potential pathogenic factors and possible therapeutic offensives. The goal of present study was to investigate the simultaneous expression of CGRP and precursor of PACAP1-38 (preproPACAP) in the central region of the TS in a time-dependent manner following TS activation in rats.

Methods: The right whisker pad of rats was injected with 50 μl Complete Freund's Adjuvant (CFA) or saline. A mechanical allodynia test was performed with von Frey filaments before and after treatment. Transcardial perfusion of the animals was initiated 24, 48, 72 and 120 h after injection, followed by the dissection of the nucleus trigeminus caudalis (TNC). After preparation, the samples were stored at - 80 °C until further use. The relative optical density of CGRP and preproPACAP was analyzed by Western blot. One-way ANOVA and Kruskal-Wallis followed by Tukey post hoc test were used to evaluate the data. Regression analysis was applied to explore the correlation between neuropeptides expression and hyperalgesia.

Results: Orofacial CFA injection resulted in significant CGRP and preproPACAP release in the TNC 24, 48, 72 and 120 h after the treatment. The level of neuropeptides reached its maximum at 72 h after CFA injection, corresponding to the peak of facial allodynia. Negative, linear correlation was detected between the expression level of neuropeptides and value of mechanonociceptive threshold.

Conclusion: This is the first study which suggests that the expression of CGRP and preproPACAP simultaneously increases in the central region of activated TS and it influences the formation of mechanical hyperalgesia. Our results contribute to a better understanding of migraine pathogenesis and thereby to the development of more effective therapeutic approaches.

Citing Articles

The role of kynurenines in migraine-related neuroimmune pathways.

Kortesi T, Nagy-Grocz G, Vecsei L J Headache Pain. 2024; 25(1):129.

PMID: 39107712 PMC: 11304619. DOI: 10.1186/s10194-024-01833-z.


Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders.

Karsan N, Edvinsson L, Vecsei L, Goadsby P Ann Clin Transl Neurol. 2024; 11(7):1654-1668.

PMID: 38887982 PMC: 11251486. DOI: 10.1002/acn3.52119.


From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.

Tanaka M, Szabo A, Kortesi T, Szok D, Tajti J, Vecsei L Cells. 2023; 12(22).

PMID: 37998384 PMC: 10670698. DOI: 10.3390/cells12222649.


Involvement of the Transient Receptor Channels in Preclinical Models of Musculoskeletal Pain.

Kudsi S, Viero F, Pereira L, Trevisan G Curr Neuropharmacol. 2023; 22(1):72-87.

PMID: 37694792 PMC: 10716882. DOI: 10.2174/1570159X21666230908094159.


Calcitonin Gene-Related Peptide-Mediated Trigeminal Ganglionitis: The Biomolecular Link between Temporomandibular Disorders and Chronic Headaches.

Sangalli L, Eli B, Mehrotra S, Sabagh S, Fricton J Int J Mol Sci. 2023; 24(15).

PMID: 37569575 PMC: 10418780. DOI: 10.3390/ijms241512200.


References
1.
Malick A, Burstein R . Peripheral and central sensitization during migraine. Funct Neurol. 2001; 15 Suppl 3:28-35. View

2.
Ren K, Dubner R . Inflammatory Models of Pain and Hyperalgesia. ILAR J. 2001; 40(3):111-118. DOI: 10.1093/ilar.40.3.111. View

3.
Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J . CGRP may play a causative role in migraine. Cephalalgia. 2002; 22(1):54-61. DOI: 10.1046/j.1468-2982.2002.00310.x. View

4.
Buzzi M, Moskowitz M . The trigemino-vascular system and migraine. Pathol Biol (Paris). 1992; 40(4):313-7. View

5.
Morgan J, Gebhart G . Characterization of a model of chronic orofacial hyperalgesia in the rat: contribution of NA(V) 1.8. J Pain. 2008; 9(6):522-31. DOI: 10.1016/j.jpain.2008.01.326. View